Cesar Diaz-Torné (Cèsar Díaz-Torné, César Díaz-Torné, Cesar Diaz-Torne, Cesar Díaz-Torné)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 32

Top Venues

RMD open

Medicina (Kaunas, Lithuania)

Biomolecules

Journal of clinical medicine

Universitat Autònoma de Barcelona Facultat de Medicina

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Universitat Autònoma de Barcelona Facultat de Medicina

Spain

Associate Professor :: Sant Pau

Hospital de la Santa Creu i Sant Pau Oct 01 2007

Spain

Consultant :: Rheumatology

Publications

Esteban Rubio Romero, Cesar Diaz-Torné, María José Moreno-Martínez, Julen De-Luz
Methotrexate treatment strategies for rheumatoid arthritis: a scoping review on doses and administration routes. BMC rheumatology 8 (1) (2024)
Cesar Diaz-Torné, Maria Antonia Pou, Chiara Gasteiger, Nicola Dalbeth
'Gout was like the boss'. A qualitative study exploring the impact of gout on employment. RMD open 10 (3) (2024)
Cristina Martinez-Molina, Cesar Diaz-Torné, Hye Sang Park, Anna Feliu Ribera, Silvia Vidal, Hèctor Corominas
Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis. Medicina (Kaunas, Lithuania) 60 (3) (2024)
Esteban Rubio Romero, Cesar Diaz-Torné, María José Moreno-Martínez, Julen De-Luz
Methotrexate treatment strategies for rheumatoid arthritis: a scoping review on doses and administration routes. BMC rheumatology 8 (1) (2024)
Cristina Martinez-Molina, Anna Feliu Ribera, Hye Sang Park, Ana Juanes, Cesar Diaz-Torné, Silvia Vidal, Hèctor Corominas
Are There Sex-Related Differences in the Effectiveness of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients? Journal of clinical medicine 13 (8) (2024)
Cesar Diaz-Torné, Maria Antonia Pou, Chiara Gasteiger, Nicola Dalbeth
'Gout was like the boss'. A qualitative study exploring the impact of gout on employment. RMD open 10 (3) (2024)
Cristina Martinez-Molina, Cesar Diaz-Torné, Hye Sang Park, Anna Feliu Ribera, Silvia Vidal, Hèctor Corominas
Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis. Medicina (Kaunas, Lithuania) 60 (3) (2024)
Cristina Martinez-Molina, Cesar Diaz-Torné, Hye Sang Park, Anna Feliu Ribera, Silvia Vidal, Hèctor Corominas
Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis. Medicina (Kaunas, Lithuania) 60 (3) (2024)
Helena Codes-Méndez, Luis Sainz, Hye Sang Park, Hèctor Corominas, Cesar Diaz-Torné
Application of the 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease in a seronegative rheumatoid arthritis cohort. RMD open 10 (2) (2024)
Helena Codes-Méndez, Luis Sainz, Hye Sang Park, Hèctor Corominas, Cesar Diaz-Torné
Application of the 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease in a seronegative rheumatoid arthritis cohort. RMD open 10 (2) (2024)
Cristina Martinez-Molina, Ignasi Gich, Cesar Diaz-Torné, Hye Sang Park, Anna Feliu Ribera, Silvia Vidal, Hèctor Corominas
Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study. Scientific reports 14 (1) (2024)
Helena Codes-Méndez, Luis Sainz, Hye Sang Park, Hèctor Corominas, Cesar Diaz-Torné
Application of the 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease in a seronegative rheumatoid arthritis cohort. RMD open 10 (2) (2024)
Helena Codes-Méndez, Luis Sainz, Hye Sang Park, Hèctor Corominas, Cesar Diaz-Torné
Application of the 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease in a seronegative rheumatoid arthritis cohort. RMD open 10 (2) (2024)
Cristina Martinez-Molina, Anna Feliu Ribera, Hye Sang Park, Ana Juanes, Cesar Diaz-Torné, Silvia Vidal, Hèctor Corominas
Are There Sex-Related Differences in the Effectiveness of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients? Journal of clinical medicine 13 (8) (2024)
Cristina Martinez-Molina, Cesar Diaz-Torné, Hye Sang Park, Anna Feliu Ribera, Silvia Vidal, Hèctor Corominas
Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis. Medicina (Kaunas, Lithuania) 60 (3) (2024)
Cristina Martinez-Molina, Ignasi Gich, Cesar Diaz-Torné, Hye Sang Park, Anna Feliu Ribera, Silvia Vidal, Hèctor Corominas
Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study. Scientific reports 14 (1) (2024)
Cesar Diaz-Torné, Maria Antonia Pou, Chiara Gasteiger, Nicola Dalbeth
'Gout was like the boss'. A qualitative study exploring the impact of gout on employment. RMD open 10 (3) (2024)
Cristina Martinez-Molina, Ignasi Gich, Cesar Diaz-Torné, Hye Sang Park, Anna Feliu Ribera, Silvia Vidal, Hèctor Corominas
Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study. Scientific reports 14 (1) (2024)
María Angels Ortiz, Cesar Diaz-Torné, Juan Jose De Agustin, Paula Estrada, Delia Reina, María Victoria Hernandez, Hye Sang, Carlos Zamora, Elisabet Cantó, Hèctor Corominas, Silvia Vidal
Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response. Biomolecules 14 (1) (2023)
María Angels Ortiz, Cesar Diaz-Torné, Juan Jose De Agustin, Paula Estrada, Delia Reina, María Victoria Hernandez, Hye Sang, Carlos Zamora, Elisabet Cantó, Hèctor Corominas, Silvia Vidal
Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response. Biomolecules 14 (1) (2023)
María Angels Ortiz, Cesar Diaz-Torné, Juan Jose De Agustin, Paula Estrada, Delia Reina, María Victoria Hernandez, Hye Sang, Carlos Zamora, Elisabet Cantó, Hèctor Corominas, Silvia Vidal
Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response. Biomolecules 14 (1) (2023)
María Angels Ortiz, Cesar Diaz-Torné, Juan Jose De Agustin, Paula Estrada, Delia Reina, María Victoria Hernandez, Hye Sang, Carlos Zamora, Elisabet Cantó, Hèctor Corominas, Silvia Vidal
Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response. Biomolecules 14 (1) (2023)
Anais Mariscal, Carlos Zamora, Cesar Diaz-Torné, María Angels Ortiz, Juan José de Agustín, Delia Reina, Paula Estrada, Patricia Moya, Hèctor Corominas, Sílvia Vidal
Increase of Circulating Monocyte-Platelet Conjugates in Rheumatoid Arthritis Responders to IL-6 Blockage. International journal of molecular sciences 23 (10) (2022)
Jessica D Murillo-Saich, Cesar Diaz-Torné, María Angels Ortiz, Roxana Coras, Paulo Vinicius Gil Alabarse, Anders Bay Nord, Hèctor Corominas, Silvia Vidal, Mónica Guma
Metabolomics profiling predicts outcome of tocilizumab in rheumatoid arthritis: an exploratory study. Metabolomics : Official journal of the Metabolomic Society 17 (9) (2021)
Berta Magallares, David Lobo-Prat, Ivan Castellvi, Patricia Moya, Ignasi Gich, Laura Martinez-Martinez, Hye Sang Park, Ana Milena Millán, Ana Laiz, Cesar Diaz-Torné, Susana Fernandez, Hèctor Corominas
Assessment of EULAR/ACR-2019, SLICC-2012 and ACR-1997 Classification Criteria in SLE with Longstanding Disease. Journal of clinical medicine 10 (11) (2021)
Cesar Diaz-Torné, M Angels Ortiz, Andrea Garcia-Guillen, Sicylle Jeria-Navarro, Lluís Sainz, Susana Fernandez-Sanchez, Hèctor Corominas, Silvia Vidal
The inflammatory role of silent urate crystal deposition in intercritical gout. Rheumatology (Oxford, England) 60 (11) (2021)
Marta Novella Navarro, José Luis Cabrera-Alarcon, Cesar Diaz-Torné, Francisco Aramburu-Muñoz, Iustina Janta, Maria Carmen Ortega de la O, Alejandro Prada-Ojeda, Luis Sala-Icardo, Ana Urruticoechea-Arana, Paloma García de la Peña Lefebvre, Enrique Calvo-Aranda
A treat-to-target approach for gout confers renoprotective effect in patients with chronic kidney disease stage 3. Rheumatology international 40 (7) (2020)
Neus Quilis, Paloma Vela, Boris A Blanco Cáceres, Cesar Diaz-Torné, Enrique Calvo-Aranda, Francisca Sivera, Alejandro Prada-Ojeda, Fernando Pérez Ruiz, Eliseo Pascual, Mariano Andrés
Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland. Annals of the rheumatic diseases (2020)
Carlos Sanchez-Piedra, Cesar Diaz-Torné, Javier Manero, José M Pego-Reigosa, Íñigo Rúa-Figueroa, Miguel Angel González-Gay, Juan Gomez-Reino, José María Álvaro-Gracia, null null
Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Annals of the rheumatic diseases 79 (7) (2020)
Juan José de Agustín de Oro, Alba Erra, Andrés Ponce, Carmen Moragues, Cesar Diaz-Torné, Delia Reina Sanz, Estefanía Moreno, Julio Ramírez, Lourdes Mateo Soria, Manel Pujol Busquets, Patricia Moya, Pilar Santo-Panero, Sergi Ros-Expósito, Francisco Javier Narváez, Raimon Sanmartí, María Jesús García de Yébenes, Loreto Carmona
Measuring inflammation in rheumatoid arthritis with a new clinical and ultrasound index: development and initial validation. Rheumatology international 39 (12) (2019)
Cesar Diaz-Torné, María Angels Ortiz, Mónica Sarmiento, César Díaz-López, Hèctor Corominas, Jordi Casademont, Silvia Vidal
Rituximab levels are associated with the B cell homeostasis but not with the clinical response in patients with rheumatoid arthritis. European journal of rheumatology 6 (2) (2019)
Cesar Diaz-Torné, Carme Moragues, Elide Toniolo, Carme Geli, Iván Castellví, Patricia Moya, Ignasi Gich, Josep M Llobet
Impact of ultrasonography on treatment decision in rheumatoid arthritis: the IMPULSAR study. Rheumatology international 37 (6) (2017)

Cesar Diaz-Torné.css-eqlu8i{font-size:small;padding-left:4px;} (Cèsar Díaz-Torné, César Díaz-Torné, Cesar Diaz-Torne, Cesar Díaz-Torné)

Publication Activity (10 Years)

Top Topics

Top Venues

Cesar Diaz-Torné (Cèsar Díaz-Torné, César Díaz-Torné, Cesar Diaz-Torne, Cesar Díaz-Torné)